Rachel Rosenthal is a Principal Scientist II at Achilles Therapeutics plc since February 2021. Prior to joining Achilles Therapeutics, Rachel worked as a Postdoctoral Researcher at The Francis Crick Institute from September 2019 to February 2021 and at UCL from April 2018 to September 2019. Rachel holds a Bachelor of Science (BSc) in Chemical Engineering from Princeton University, a Doctor of Philosophy (PhD) in Cancer Genetics from UCL, and a Master of Science (MS) in Systems Biology from ETH Zürich.
January 1, 2024 - present
January, 2023
February, 2021